Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
17 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02584933 | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | active not recruiting | Phase 4 | 233 | Novartis PharmaceuticalsINDUSTRY | 21 | Sep 17, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT04877522 |
| Asciminib Roll-over Study |
| recruiting |
| Phase 4 |
| 347 |
| Novartis PharmaceuticalsINDUSTRY |
| 29 |
| Jul 6, 2026 |
| clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT02476968 | To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer(ORZORA) | completed | Phase 4 | 181 | AstraZenecaINDUSTRY | 8 | Sep 10, 2022 | clinicaltrials |
| NCT02092467 | Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | completed | Phase 4 | 4,372 | PfizerINDUSTRY | 30 | Aug 17, 2021 | clinicaltrials |
| NCT01588184 | An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study | completed | Phase 4 | 95 | Hoffmann-La RocheINDUSTRY | 21 | Nov 5, 2020 | clinicaltrials |
| NCT00430352 | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. | completed | Phase 4 | 545 | Hoffmann-La RocheINDUSTRY | 24 | Aug 14, 2017 | clinicaltrials |
| NCT01061177 | Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase('MACS1252) | completed | Phase 4 | 1,090 | Novartis PharmaceuticalsINDUSTRY | 26 | Feb 24, 2017 | clinicaltrials |
| NCT01203917 | Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC(IFUM) | completed | Phase 4 | 1,060 | AstraZenecaINDUSTRY | 13 | Jan 2, 2017 | clinicaltrials |
| NCT02564094 | A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies | completed | Phase 4 | 54 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02564107 | A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease | completed | Phase 4 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02567331 | A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer | completed | Phase 4 | 28 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02581423 | A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer | completed | Phase 4 | 63 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT01950871 | Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning(PHSTT-01) | terminated | Phase 4 | 80 | Advanced Medical Diagnostics s.a.INDUSTRY | 18 | Jan 5, 2015 | clinicaltrials |
Data updated 12 days agoSource updated unknownsource: clinicaltrials